{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:11:57Z","timestamp":1790518317696,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.critrevonc.2013.07.017","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T08:15:14Z","timestamp":1376986514000},"page":"667-679","source":"Crossref","is-referenced-by-count":8,"title":["The one-two punch: Combination treatment in chronic myeloid leukemia"],"prefix":"10.1016","volume":"88","author":[{"given":"Kendra L.","family":"Sweet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Hazlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6022","key":"10.1016\/j.critrevonc.2013.07.017_bib0005","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2019 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0010","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"Journal of the National Cancer Institute"},{"issue":"5405","key":"10.1016\/j.critrevonc.2013.07.017_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.07.017_bib0020","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.07.017_bib0025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.critrevonc.2013.07.017_bib0030","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.07.017_bib0035","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncology"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.07.017_bib0040","first-page":"603","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study","volume":"118","author":"Mahon","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.07.017_bib0045","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.critrevonc.2013.07.017_bib0050","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.critrevonc.2013.07.017_bib0055","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.critrevonc.2013.07.017_bib0060","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"suppl","key":"10.1016\/j.critrevonc.2013.07.017_bib0065","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/jco.2012.30.15_suppl.6504","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up","volume":"30","author":"Hochhaus","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.07.017_bib0070","first-page":"1676","article-title":"Enestnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.07.017_bib0075","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochemical Pharmacology"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.07.017_bib0080","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.07.017_bib0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.07.017_bib0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.07.017_bib0095","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.07.017_bib0100","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"issue":"Pt 8","key":"10.1016\/j.critrevonc.2013.07.017_bib0105","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"Journal of Cell Science"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.07.017_bib0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nature Reviews Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.07.017_bib0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates BCR-ABL signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.07.017_bib0120","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Cancer Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0125","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1182\/blood-2011-01-332569","article-title":"STAT5 as a CML target: STATinib therapies?","volume":"117","author":"Turhan","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.07.017_bib0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR\/ABL","volume":"183","author":"Carlesso","year":"1996","journal-title":"Journal of Experimental Medicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0135","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0140","series-title":"Study to Assess the Safety of Azd1480 in Patients with Myeloproliferative Diseases","author":"Verstovsek","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0145","series-title":"CEP-701 (Lestaurtinib) in Myelofibrosis","author":"Silverman","year":"2012"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.07.017_bib0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0155","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0160","series-title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia","author":"Brown","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0165","series-title":"Safety Study Evaluating Twice-Daily Administration of Cyt387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis","author":"Sterling","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0170","series-title":"Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET)","author":"Tefferi","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0175","series-title":"A Phase 1 Study of LY2784544 in Patients With Jak2 V617F-Positive Myeloproliferative Disorders","author":"Eli Lilly and Company","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0180","series-title":"A Phase 2 Study of LY278544 in Patients With Myeloproliferative Neoplasms","author":"Eli Lilly and Company","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0185","series-title":"A Phase 1\/2, Open-Label, Dose-Escalation Multi-Center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-Polycythemia Vera MF, or Post-Essential Thrombocythemia MF","author":"Verstovsek","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0190","series-title":"Jakafi (Ruxolitinib) Prescribing Information","author":"Jakafi","year":"2011"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0195","series-title":"Paper Presented At: Annual Meeting of the American Society of Clinical Oncology","article-title":"Preliminary safety and efficacy of ruxolitinib in patients with primary and secondary myelofibrosis with platelet counts of 50\u2013100(10(9) (abstract 6630)","author":"Talpaz","year":"2012"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0200","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0205","series-title":"A Multi-National Open-Label Phase II Study of the JAK Inhibitor INC424 in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis","author":"Novartis Pharmaceuticals","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0210","series-title":"Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients with Myelofibrosis","author":"Verstovsek","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0215","series-title":"A Phase I\/II Study to Determine the Safety and Efficacy of Ruxolitinib, a JAK1\/JAK2 Inhibitor, in Subjects with Relapsed or Refractory Acute Leukemia","author":"Verstovsek","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0220","series-title":"INCB018424 in Patients with Advanced Hematologic Malignancies","author":"Ravandi-Kashani","year":"2012"},{"issue":"20","key":"10.1016\/j.critrevonc.2013.07.017_bib0225","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0230","series-title":"A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma","author":"Vose","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0235","series-title":"Study with SAR302503 in Patients with Polycythemia Vera or Essential Thrombocythemia","author":"Sanofi-Aventis","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0240","series-title":"Phase II Study of SB1518 for Patients with Myelodysplastic Syndrome (MDS)","author":"Garcia-Manero","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0245","series-title":"A Phase 1\/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies","author":"Verstovsek","year":"2012"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.07.017_bib0250","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/jco.2011.29.15_suppl.6515","article-title":"Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis","volume":"29","author":"Deeg","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.07.017_bib0255","first-page":"282","article-title":"Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis","volume":"118","author":"Komrokji","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0260","series-title":"A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies","author":"Younes","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0265","series-title":"A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies","author":"Younes","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0270","series-title":"Phase I, Open-Label, Dose-Escalation Study of ISIS-STAT3Rx, Administered to Patients with Advanced Cancers","author":"Isis Pharmaceuticals","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0275","series-title":"A Dose-Escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients with Relapsed or Refractory Hematologic Malignancies (Phase 1)","author":"Otsuka Pharmaceutical","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0280","series-title":"Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","author":"Brown","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0285","series-title":"Multiple Ascending Dose (MAD) Combination in Subjects with Multiple Myeloma","author":"Bristol-Myers-Squibb","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0290","series-title":"Dasatinib (BMS-354825) Combined with SMO Inhibitor (BMS-833923; XL139) in CML with Resistance or Suboptimal Response to a Prior TKI","author":"Bristol-Myers-Squibb","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0295","series-title":"GDC-0449 in Treating Patients with High-risk First Remission or Relapsed Multiple Myeloma Who Received An Autologous Stem Cell Transplant","author":"Huff","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0300","series-title":"A Phase 2 Study With IPI-926 in Patients With Myelofibrosis","author":"Verstovsek","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0305","series-title":"A Single-Arm Dose-Finding Phase IB Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Have Failed Prior Therapy With Other BCR-ABL Tyrosine-Kinase Inhibitors","author":"Novartis Pharmaceuticals","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0310","series-title":"A Study of PF-04449913 in Select Hematologic Malignancies","author":"Pfizer Inc","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0315","author":"Pfizer Inc","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0320","series-title":"Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients","author":"de Haan","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0325","series-title":"An Open-Label, Dose-Escalation Phase I\/II Study of PRI-724 for Patients with Advanced Myeloid Malignancies","author":"Cortes","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0330","author":"Hege","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.017_bib0335","series-title":"A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients with Advanced Solid Tumors or Lymphoma","author":"Astellas Pharma Inc","year":"2012"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.07.017_bib0340","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","article-title":"Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML","volume":"36","author":"Nair","year":"2012","journal-title":"Leukemia Research"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0345","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.07.017_bib0350","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.molonc.2012.02.002","article-title":"Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling","volume":"6","author":"Nam","year":"2012","journal-title":"Molecular Oncology"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.07.017_bib0355","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2011.143","article-title":"The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis","volume":"25","author":"Mar","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.07.017_bib0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1758834010366430","article-title":"Targeting the Hedgehog pathway in cancer","volume":"2","author":"Gupta","year":"2010","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.07.017_bib0365","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of BCR-ABL-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"issue":"7239","key":"10.1016\/j.critrevonc.2013.07.017_bib0370","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"issue":"7063","key":"10.1016\/j.critrevonc.2013.07.017_bib0375","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nature04108","article-title":"Wnt signalling regulates adult hippocampal neurogenesis","volume":"437","author":"Lie","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.07.017_bib0380","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/ni1006-1021","article-title":"Hematopoietic stem cell biology: too much of a Wnt thing","volume":"7","author":"Trowbridge","year":"2006","journal-title":"Nature Immunology"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.07.017_bib0385","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.07.017_bib0390","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.07.017_bib0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of BCR-ABL","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"issue":"52","key":"10.1016\/j.critrevonc.2013.07.017_bib0400","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/sj.onc.1209038","article-title":"Involvement of PP2A in viral and cellular transformation","volume":"24","author":"Arroyo","year":"2005","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.critrevonc.2013.07.017_bib0405","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","article-title":"Targeting SET\/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy","volume":"30","author":"Switzer","year":"2011","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.07.017_bib0410","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.07.017_bib0415","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.07.017_bib0420","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies","volume":"145","author":"Teachey","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.07.017_bib0425","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony","volume":"285","author":"Foster","year":"2010","journal-title":"Journal of Biological Chemistry"},{"issue":"28","key":"10.1016\/j.critrevonc.2013.07.017_bib0430","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Carayol","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"17","key":"10.1016\/j.critrevonc.2013.07.017_bib0435","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.07.017_bib0440","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.07.017_bib0445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.07.017_bib0450","first-page":"3781","volume":"118","author":"Rousselot","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7240","key":"10.1016\/j.critrevonc.2013.07.017_bib0455","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0460","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.07.017_bib0465","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.critrevonc.2013.07.017_bib0470","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.07.017_bib0475","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.critrevonc.2013.07.017_bib0480","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","article-title":"Histone deacetylase inhibitors specifically kill nonproliferating tumour cells","volume":"23","author":"Burgess","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.07.017_bib0485","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nature Reviews Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.07.017_bib0490","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.07.017_bib0495","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4161\/cc.8.21.9852","article-title":"The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia","volume":"8","author":"Chen","year":"2009","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.07.017_bib0500","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1758834012445574","article-title":"Heat shock protein 90 inhibition: rationale and clinical potential","volume":"4","author":"Den","year":"2012","journal-title":"Therapeutic Advances in Medical Oncology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T06:56:14Z","timestamp":1596351374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1040842813001686"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.017","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}